There is a lot to learn from each other, says an old adage. Perhaps for the first time in the pharmaceutical industry after research and technology alliances, there is now an alliance by six pharma companies for adoption of best manufacturing practices.
The pharma companies include Lupin Pharmaceuticals, Aurobindo Pharma, Zydus Cadila, Orchid Chemicals and Pharmaceuticals, Ranbaxy Laboratories and Dr Reddy’s Laboratories in the alliance — LAZORR — which aims to improve productivity using the best practices and counter the soaring input costs in the industry.
The alliance will help to bring assured quality by the domestic manufacturers using the current good manufacturing practices (cGMP) thus giving a green quality signal to the global pharmaceutical industry.
“The alliance aims to address operational challenges with the rising inputs costs both power and raw materials to improve the production efficiency. Though the above said pharma companies are a competition amongst themselves, it would help in branding Indian APIs and formulations as the est quality products to the global markets,’’ say industry experts.
A Lupin spokesperson told FE, “LAZORR is a collaborative platform that was created to help member companies — six of lndia’s largest pharma companies — share best practices, in a bid to improve efficiency; bring down rising operating costs as also help each other compete better and more effectively in the global market place. This initiative becomes more significant in the current scenario given the fact that India has emerged as the best quality manufacturer of generic drugs in the world.”
LAZORR is a pioneering effort in the Indian pharma industry and will benefit all players, Orchid spokesperson says. Aurobindo officials say power is a major issue apart from water usage and material costs which the alliance would collectively focus on and reduce operational challenges that are affecting the industry.
Incidentally, the FDA has also started talking about early adoption of new technological advances by the industry for modern quality management techniques, including implementation of quality systems approaches and enhance the consistency and coordination of FDA’s drug quality regulatory programs, in part, by integrating enhanced quality systems approaches into the Agency’s business processes and regulatory policies concerning review and inspection activities.
The alliance would foster cGMP among Indian pharma players thereby adhering to a set of codes, and guidelines for the manufacture of drugs, medical devices, diagnostic products, foods products and Active Pharmaceutical Ingredients (APIs).
“cGMP would ensure a drug with zero defects. As a